Metabolic alkalosis due to ecf volume expansion
Reading File
Quick answer: Metabolic alkalosis due to ECF volume expansion is also called "mineralocorticoid excess" or "chloride-resistant" metabolic alkalosis. It occurs when excess aldosterone (or similar hormones) causes Na+ and water retention, expanding ECF volume, while simultaneously driving H+ and K+ excretion by the kidney - maintaining the alkalosis despite the volume-replete state. Classic causes include primary hyperaldosteronism, Cushing's syndrome, and Liddle's syndrome.
Searching sources...
Finding Sources
Searching the Web
metabolic alkalosis ECF volume expansion mineralocorticoid excess mechanism
Good results. Let me read the most comprehensive sources - Costanzo Physiology and Comprehensive Clinical Nephrology, plus Brenner and Rector's Kidney.
Reading File
Reading File
Reading File
Let me search more specifically for metabolic alkalosis with ECF volume expansion (mineralocorticoid excess / chloride-resistant) and also check the Nephrology textbook more deeply.
Finding Sources
Finding Sources
Excellent! I found the key Harrison's section. Let me read it plus the Brenner & Rector details.
Reading File
Reading File
Let me read a bit more of the Brenner & Rector section for the specific causes and also fetch the key diagram image.
Reading File
I now have comprehensive information. Let me compile the full answer.
Metabolic Alkalosis Due to ECF Volume Expansion
This category of metabolic alkalosis is also called chloride-resistant alkalosis or mineralocorticoid excess alkalosis. It is characterized by ECF volume expansion, hypertension, hypokalemia, and a urine chloride > 40 mEq/L (the hallmark that distinguishes it from chloride-responsive/volume-depleted alkalosis).
Pathophysiology
The core mechanism involves excess mineralocorticoid activity (primarily aldosterone), which acts on the collecting duct principal cells to:
- Upregulate ENaC (epithelial Na+ channel) - increased Na+ reabsorption leads to ECF volume expansion and hypertension
- Increase luminal electronegativity - the Na+ reabsorption without Cl- creates a transepithelial voltage gradient that drives:
- H+ secretion (via H+-ATPase in alpha-intercalated cells) → generates new HCO3- → metabolic alkalosis
- K+ secretion (via ROMK channels) → hypokalemia
- Hypokalemia perpetuates alkalosis - K+ depletion causes intracellular acidosis, which further stimulates H+ secretion in both proximal and distal nephron, and activates H+/K+-ATPase in the collecting duct
The alkalosis is not progressive and is generally mild, partly due to "aldosterone escape": ECF volume expansion increases natriuretic peptides (e.g., ANP) and raises GFR, antagonizing the aldosterone-driven acid excretion to some degree.
- Brenner and Rector's The Kidney, pp. 732-734
- Harrison's Principles of Internal Medicine 22E, p. 418
Classification by Renin/Aldosterone Status
High Renin → Secondary Hyperaldosteronism
Renin is overproduced by the kidney, driving aldosterone excess. Total ECF may not be reduced despite "effective" volume issues:
- Renovascular hypertension (renal artery stenosis) - reduced renal perfusion triggers renin release
- Malignant / accelerated hypertension
- Renin-secreting tumor (primary reninism) - rare
- Estrogen use - increases renin substrate (angiotensinogen) → increased angiotensin II → secondary aldosteronism
Low Renin, High Aldosterone → Primary Hyperaldosteronism
Autonomous adrenal overproduction suppresses renin feedback:
| Cause | Key Features |
|---|---|
| Primary aldosteronism (Conn's syndrome) | Adrenal adenoma (most common), bilateral hyperplasia, or rarely carcinoma; classic triad: hypertension + hypokalemia + metabolic alkalosis |
| Glucocorticoid-remediable hyperaldosteronism (GRA) | Autosomal dominant; chimeric gene fuses CYP11B1 promoter with CYP11B2 aldosterone synthase - ACTH drives excess aldosterone; corrected by glucocorticoids; associated with severe hypertension and stroke risk |
| Cushing's syndrome/disease | High glucocorticoids cause alkalosis via cross-reactivity at mineralocorticoid receptors + coexisting mineralocorticoid (deoxycorticosterone, corticosterone) hypersecretion |
| Adrenal enzyme defects (11β-hydroxylase, 17α-hydroxylase deficiency) | Accumulation of mineralocorticoid precursors (deoxycorticosterone) |
Low Renin, Low Aldosterone (Pseudohyperaldosteronism)
ENaC is constitutively active despite low aldosterone:
| Cause | Mechanism |
|---|---|
| Liddle's syndrome | Gain-of-function mutation in β or γ subunit of ENaC (disrupts PY motif binding to Nedd4 ubiquitin ligase → increased ENaC surface expression); autosomal dominant; severe childhood-onset hypertension, hypokalemia, metabolic alkalosis; does NOT respond to spironolactone (aldosterone receptor blocker); responds to amiloride/triamterene (direct ENaC blockers) |
| Apparent mineralocorticoid excess (AME) | Deficiency of 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) → cortisol not inactivated to cortisone in kidney → cortisol occupies and activates mineralocorticoid receptors; same effect from licorice ingestion (glycyrrhizic acid inhibits 11β-HSD2) |
- Brenner and Rector's The Kidney, pp. 732-735
- Harrison's Principles of Internal Medicine 22E, p. 418
Key Diagnostic Feature: Urine Chloride
| Urine Cl- | Category | Interpretation |
|---|---|---|
| < 20 mEq/L | Chloride-responsive | Volume-depleted (vomiting, diuretics post-effect) - kidney is conserving Cl- |
| > 40 mEq/L | Chloride-resistant | Volume-expanded (mineralocorticoid excess) - kidney continues to waste Cl- |
Associated Findings
- Hypertension (from ECF volume expansion and Na+ retention)
- Hypokalemia (from ongoing kaliuresis)
- Polydipsia / polyuria (from persistent K+ depletion impairing urinary concentration)
- Neuromuscular symptoms of alkalosis: paresthesias, muscular cramps, tetany, and in severe cases, seizures, mental confusion, obtundation, and worsening of arrhythmias
Treatment
Principle: Treat the underlying cause; do NOT give saline (unlike chloride-responsive alkalosis).
| Cause | Treatment |
|---|---|
| Primary aldosteronism (adenoma) | Surgical adrenalectomy |
| Bilateral adrenal hyperplasia | Spironolactone / eplerenone (mineralocorticoid receptor antagonists) |
| Cushing's syndrome | Treat the source (pituitary, adrenal, ectopic ACTH) |
| GRA | Glucocorticoid administration (dexamethasone suppresses chimeric gene) |
| Liddle's syndrome | Amiloride or triamterene (NOT spironolactone) |
| AME / licorice | Stop licorice; spironolactone or amiloride |
| All cases with hypokalemia | Replenish K+ (essential, as K+ deficiency maintains alkalosis) |
If saline cannot be given (e.g., heart failure) and alkalosis must be corrected, acetazolamide (125-250 mg IV) can accelerate renal HCO3- loss, though it also causes kaliuresis and requires monitoring.
- Harrison's Principles of Internal Medicine 22E, p. 418
- Costanzo Physiology 7th Edition
Pallor definition
Pallor is the abnormal paleness or loss of normal skin/mucous membrane color, resulting from reduced oxyhemoglobin in superficial blood vessels or decreased blood flow to the skin.
Searching sources...
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Searching the Web
pallor definition clinical medicine hemoglobin skin color
Let me read the Goldman-Cecil and Symptom to Diagnosis passages more fully.
Reading File
Reading File
I now have solid, textbook-grounded information. Here is the complete answer:
Pallor - Definition
Pallor is the abnormal paleness of the skin and/or mucous membranes resulting from a reduction in the amount of oxyhemoglobin visible in the superficial vessels, or from shunting of blood away from the periphery toward critical organs.
It is a clinical sign, not a diagnosis in itself.
Key Points
Why pallor occurs
Two main mechanisms:
- Reduced hemoglobin - less oxyhemoglobin in circulating blood (e.g., anemia of any cause)
- Reduced peripheral perfusion - vasoconstriction shunts blood away from the skin to vital organs (e.g., shock, vasovagal episode, hypothermia, Raynaud's phenomenon)
Important distinction
- Pallor ≠ Anemia - pallor is a physical sign; anemia is a defined biochemical condition (low Hb). Pallor can exist without anemia (e.g., in shock or fair-skinned individuals), and anemia can exist without clinically obvious pallor.
- Skin pigmentation among healthy individuals makes pallor in the skin difficult to interpret - examining mucous membranes (conjunctiva, oral mucosa) overcomes this variable.
Sites of Examination and Clinical Significance
| Site | Clinical Value |
|---|---|
| Conjunctival mucosa | Most specific; pallor here generally indicates Hb < 9 g/dL (LR+ 16.7 for anemia) |
| Palmar creases | Failure of creases to remain pink when palm is extended → Hb typically ≤ 7-8 g/dL; LR+ of 7.9 |
| Nail beds, face | Less specific; LR+ < 5 for anemia |
| Tongue / oral mucosa | Useful in all skin types |
No single physical sign rules out anemia. Overall sensitivity and specificity of the physical exam for anemia is ~70%.
- Goldman-Cecil Medicine, Physical Findings chapter
- Symptom to Diagnosis: An Evidence-Based Guide, 4th Ed.
Common Causes
| Category | Examples |
|---|---|
| Anemia (most common) | Iron deficiency, hemolytic anemia, B12/folate deficiency, aplastic anemia, chronic disease |
| Reduced peripheral blood flow | Shock (hypovolemic, cardiogenic, septic), vasovagal syncope, Raynaud's phenomenon |
| Metabolic | Hypoglycemia |
| Others | Hypothyroidism, hypothermia, chronic illness, pain response |
Pallor vs. Anemia - Quick Summary
| Pallor | Anemia | |
|---|---|---|
| What it is | Clinical sign (visual appearance) | Defined by Hb level (lab) |
| Cause | Low Hb OR low perfusion | Low Hb / RBC mass |
| Diagnosis | By examination | By hemogram |
| Can one exist without other? | Yes (e.g., shock without anemia) | Yes (mild anemia may not cause visible pallor) |
This is a shared conversation. Sign in to Orris to start your own chat.